Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.